Drug intelligence / Profile preview

A6

Development stage: Preclinical
Modality: Small Molecules, Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

"A6" is a non-specific identifier that refers to several distinct drug candidates. These include *Bifidobacterium animalis subsp. Lactis A6 Strain*, a probiotic being investigated for Irritable Bowel Syndrome - Diarrhoea (IBS-D) for its ability to improve symptoms. It also refers to a dihydropyridine-sulfonyl derivative compound, A6, which acts as an autophagy inducer and shows potential as an anticancer agent against various carcinoma cell lines (MCF-7, A549, SKOV-3, EA.yh926). Furthermore, "compound A6" is a small molecule that enhances TFAP2β condensation to suppress the development of esophageal squamous cell carcinoma.

Other names: Bifidobacterium animalis subsp. Lactis A6 Straindihydropyridine-sulfonyl derivative A6ESCC compound A6

Targets

TFAP2B (Transcription factor AP-2 beta)

Beyond the preview

Go deeper on A6.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on A6.

Explore the full profile